# Exploring the Therapeutic Potential of Lenvatinib: A Complete Pathological Response in an Operable Case of Hepatocellular Carcinoma

## TL;DR

A 66-year-old man with liver cancer showed complete tumor response after short-term lenvatinib treatment before surgery.

## Contribution

Demonstrates lenvatinib's potential for complete pathological response in operable hepatocellular carcinoma.

## Key findings

- Short-term lenvatinib treatment led to complete pathological response in operable HCC.
- Patient achieved significant tumor reduction and successful surgery after brief treatment.
- Case suggests lenvatinib could be effective in preoperative HCC management.

## Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with increasing incidence and mortality rates. This case report presents a unique instance of a 66-year-old male patient with operable HCC who achieved a complete pathological response after short-term preoperative treatment with lenvatinib. The patient, with a history of diabetes and hypertension, was diagnosed with HCC and started on lenvatinib due to logistical reasons. Despite discontinuing the treatment after one week due to altered sensorium, a significant reduction in tumor size was observed. The patient underwent successful surgery, and the final histopathology report indicated a complete pathological response. This case highlights the potential of lenvatinib as a therapeutic option in the management of HCC, even in operable cases, and opens avenues for further research into its efficacy and applicability.